{"analyses":[{"ciLowerLimit":"0.928","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.483","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1641","paramType":"Cox Proportional Hazard","paramValue":"1.173","statisticalMethod":"Unstratified Log-rank Test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.3","upperLimit":"4.8","value":"3.8"},{"groupId":"OG001","lowerLimit":"3.8","upperLimit":"9.3","value":"6.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"226"},{"groupId":"OG001","value":"222"}],"units":"Participants"}],"description":"HRQOL was measured by standardized questionnaires (European Organization for Research and Treatment of Cancer (EORTC)) quality of life questionnaires (OLQ-C30) and its lung cancer module (QLQ-LC13). TTD in pain (chest, arm/shoulder), dyspnea, fatigue or cough was defined as time between baseline and first occurrence of increase in score of 10 points or greater from baseline in any of these 4 symptoms for at least two consecutive cycles. For those who had not shown deterioration, the data was censored at the last date when the participants completed an assessment for pain, dyspnea, fatigue or cough.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first.","id":"OG000","title":"Dacomitinib"},{"description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first.","id":"OG001","title":"Gefitinib"}],"paramType":"MEDIAN","populationDescription":"Patient reported outcomes (PRO) analysis set included all enrolled participants, who started treatment and completed a baseline PRO assessments and at least one post-baseline PRO assessment after the first dose.","reportingStatus":"POSTED","timeFrame":"Baseline until the end of treatment (up to 48 months)","title":"Health Related Quality of Life (HRQOL): Time to Deterioration (TTD) in Pain, Dyspnea, Fatigue or Cough","type":"SECONDARY","unitOfMeasure":"months"}